Ocrelizumab-induced colitis—critical review and case series from a Romanian cohort of MS patients
Ocrelizumab-induced colitis is a rare, but severe adverse event. Its incidence may be higher than expected, reaching 1,95% in our cohort of MS patients. Further reporting of such cases is essential to broaden our understanding of this side effect.
Authors
- Cristina Tiu (ORCID: https://orcid.org/0000-0001-8532-6218)
- Lucian Negreanu (ORCID: https://orcid.org/0000-0003-3042-0754)
- Elena Terecoasă (ORCID: https://orcid.org/0000-0002-6670-7557)
- Vlad Eugen Tiu (ORCID: https://orcid.org/0000-0003-4315-9292)
- Alina Flavia Tomescu
- Florin Costel DOBRITOIU
- Ileana Maria Vodă
- Luiza Răuță
- Paul Ciucur
- Andreea Ioana Mușuroi
- Nicoleta Laura Humă
Institutions
- Carol Davila University of Medicine and Pharmacy (RO)
- Clinical Emergency Hospital Bucharest (RO)
Publication Details
- Journal
- Frontiers in Neurology
- Published
- 2025-02-05
- DOI
- https://doi.org/10.3389/fneur.2025.1530438
- Citations
- 4
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 5.89